VERV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VERV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Verve Therapeutics's book value per share for the quarter that ended in Mar. 2024 was $6.96.
During the past 12 months, Verve Therapeutics's average Book Value Per Share Growth Rate was -15.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
Verve Therapeutics's current price is $5.98. Its book value per share for the quarter that ended in Mar. 2024 was $6.96. Hence, today's PB Ratio of Verve Therapeutics is 0.86.
During the past 5 years, the highest P/B Ratio of Verve Therapeutics was 4.49. The lowest was 0.86. And the median was 1.96.
Good Sign:
Verve Therapeutics Inc stock PB Ratio (=0.92) is close to 2-year low of 0.86
The historical data trend for Verve Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verve Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Book Value per Share | -0.67 | -1.46 | 7.37 | 8.93 | 7.31 |
Verve Therapeutics Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Book Value per Share | Get a 7-Day Free Trial | 8.24 | 7.50 | 7.22 | 7.31 | 6.96 |
For the Biotechnology subindustry, Verve Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Verve Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Verve Therapeutics's PB Ratio falls into.
Verve Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (599.50 | - | 0.00) | / | 81.97 | |
= | 7.31 |
Verve Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (583.07 | - | 0.00) | / | 83.82 | |
= | 6.96 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Verve Therapeutics (NAS:VERV) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of Verve Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Krishna Yeshwant | director, 10 percent owner | C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043 |
Allison Dorval | officer: Chief Financial Officer | C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
Fred T. Fiedorek | officer: Chief Medical Officer | 55 BALDWIN LANE, PRINCETON NJ 08540 |
Joan Nickerson | officer: Chief Administrative Officer | C/O VERVE THERAPEUTICS, INC., 201 BROOKLINE AVENUE, SUITE 601, BOSTON MA 02215 |
Andrew Bellinger | officer: Chief Scientific Officer | 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Gv 2017 Gp, L.l.c. | 10 percent owner | 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043 |
Alphabet Inc. | other: Member of 10% Group | 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043 |
Sekar Kathiresan | director, 10 percent owner, officer: Chief Executive Officer | 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Lonnel Coats | director | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
Fmr Llc | 10 percent owner, other: See Remark 1 | 245 SUMMER STREET, BOSTON MA 02210 |
Alexander Cumbo | director | 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142 |
Burt A Adelman | director, 10 percent owner | DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
Andrew D. Ashe | officer: See Remarks | C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
Logos Global Management Lp | 10 percent owner | 1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129 |
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
From GuruFocus
By sperokesalga sperokesalga • 03-03-2023
By ACCESSWIRE • 11-17-2023
By Marketwired • 09-21-2023
By Marketwired • 11-07-2023
By PRNewswire PRNewswire • 12-13-2022
By sperokesalga sperokesalga • 06-15-2023
By Marketwired • 08-10-2023
By Marketwired • 08-03-2023
By Marketwired • 10-23-2023
By PRNewswire PRNewswire • 12-27-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.